Insight Molecular Diagnostics Inc. Common Stock (IMDX)
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Insight Molecular Diagnostics Inc. Common Stock (IMDX) is listed on Nasdaq, where it has traded since December 30, 2015.
- Listed On
- Nasdaq
- Listed Since
- December 30, 2015
- Employees
- 58
- Market Cap
- $104M
About Insight Molecular Diagnostics Inc. Common Stock
Insight Molecular Diagnostics Inc is a pioneering diagnostics technology company whose mission is to democratize access to novel molecular diagnostic testing to improve patient outcomes. The Company's flagship technology quantifies a molecular biomarker known as donor-derived cell-free DNA (dd-cfDNA). It is also in the process of rebranding its RUO test kit, GraftAssure, as GraftAssureIQ, and rebranding its future in-vitro diagnostic (IVD) test kit as GraftAssureDx. The company geographically operates in the United States, the United Kingdom, Europe, and the Asia-Pacific regions, with maximum revenue generated from the USA.
Institutional ownership
In 13F filings for the quarter ended June 30, 2026, 38 institutions reported holding IMDX, with 18.5 million shares worth $108.9 million in aggregate. The largest reported holder was Broadwood Capital, with 12.7 million shares worth $74.8 million. Of the 5 largest holders listed below, 4 added shares and 1 reduced its position during the quarter.
| Institution | Shares | Value | Quarter change |
|---|---|---|---|
| Broadwood Capital | 12,684,884 | $75M | Added 6.31% |
| Awm Investment Company | 2,836,692 | $17M | Added 1.08% |
| Vanguard | 866,198 | $5M | Added 28.23% |
| Pura Vida Investments | 484,845 | $3M | Reduced 48.81% |
| Family Office Research | 368,849 | $2M | Added 189.83% |
Form 13F is a quarterly report that institutional investment managers with at least $100 million in qualifying securities file with the SEC. It lists long positions as of the last day of the quarter and is due within 45 days of quarter end, so these holdings describe that date rather than today.
Frequently asked questions
What is IMDX?
Insight Molecular Diagnostics Inc. Common Stock (IMDX) is listed on Nasdaq, where it has traded since December 30, 2015.
Who are the largest institutional holders of IMDX?
In 13F filings for the quarter ended June 30, 2026, the largest reported holders of IMDX were Broadwood Capital, Awm Investment Company and Vanguard.
How many institutions own IMDX?
38 institutions reported a position in IMDX for the quarter ended June 30, 2026, worth $108.9 million in total.
Did institutions buy or sell IMDX last quarter?
Of the 5 largest reported holders, 4 added shares and 1 reduced its position during the quarter. Every reported holder and its change is on the SentiSense ownership page for IMDX.
Every reported institutional holder, plus insider and congressional trades in IMDX, on SentiSense.